These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 16758298)

  • 1. Role of SUMO/Ubc9 in DNA damage repair and tumorigenesis.
    Moschos SJ; Mo YY
    J Mol Histol; 2006 Sep; 37(5-7):309-19. PubMed ID: 16758298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ubc9- and mms21-mediated sumoylation counteracts recombinogenic events at damaged replication forks.
    Branzei D; Sollier J; Liberi G; Zhao X; Maeda D; Seki M; Enomoto T; Ohta K; Foiani M
    Cell; 2006 Nov; 127(3):509-22. PubMed ID: 17081974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ATPase-dependent control of the Mms21 SUMO ligase during DNA repair.
    Bermúdez-López M; Pociño-Merino I; Sánchez H; Bueno A; Guasch C; Almedawar S; Bru-Virgili S; Garí E; Wyman C; Reverter D; Colomina N; Torres-Rosell J
    PLoS Biol; 2015 Mar; 13(3):e1002089. PubMed ID: 25764370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Ubc9, an E2 ligase for SUMO conjugation, with p53 is regulated by phosphorylation of p53.
    Lin JY; Ohshima T; Shimotohno K
    FEBS Lett; 2004 Aug; 573(1-3):15-8. PubMed ID: 15327968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SIM-dependent enhancement of substrate-specific SUMOylation by a ubiquitin ligase in vitro.
    Parker JL; Ulrich HD
    Biochem J; 2014 Feb; 457(3):435-40. PubMed ID: 24224485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of the SUMO modification system is required for the accumulation of RAD51 at sites of DNA damage.
    Shima H; Suzuki H; Sun J; Kono K; Shi L; Kinomura A; Horikoshi Y; Ikura T; Ikura M; Kanaar R; Igarashi K; Saitoh H; Kurumizaka H; Tashiro S
    J Cell Sci; 2013 Nov; 126(Pt 22):5284-92. PubMed ID: 24046452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Smt3/SUMO and Ubc9 are required for efficient APC/C-mediated proteolysis in budding yeast.
    Dieckhoff P; Bolte M; Sancak Y; Braus GH; Irniger S
    Mol Microbiol; 2004 Mar; 51(5):1375-87. PubMed ID: 14982631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Purification and activity assays for Ubc9, the ubiquitin-conjugating enzyme for the small ubiquitin-like modifier SUMO.
    Yunus AA; Lima CD
    Methods Enzymol; 2005; 398():74-87. PubMed ID: 16275321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel mechanism whereby BRCA1/1a/1b fine tunes the dynamic complex interplay between SUMO-dependent/independent activities of Ubc9 on E2-induced ERalpha activation/repression and degradation in breast cancer cells.
    Xu J; Watkins T; Reddy A; Reddy ES; Rao VN
    Int J Oncol; 2009 Apr; 34(4):939-49. PubMed ID: 19287951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ubc9 fusion-directed SUMOylation (UFDS): a method to analyze function of protein SUMOylation.
    Jakobs A; Koehnke J; Himstedt F; Funk M; Korn B; Gaestel M; Niedenthal R
    Nat Methods; 2007 Mar; 4(3):245-50. PubMed ID: 17277783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Covalent conjugation of the equine infectious anemia virus Gag with SUMO.
    Wang J; Wen S; Zhao R; Qi J; Liu Z; Li W; An J; Wood C; Wang Y
    Biochem Biophys Res Commun; 2017 May; 486(3):712-719. PubMed ID: 28342872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. S. cerevisiae Mre11 recruits conjugated SUMO moieties to facilitate the assembly and function of the Mre11-Rad50-Xrs2 complex.
    Chen YJ; Chuang YC; Chuang CN; Cheng YH; Chang CR; Leng CH; Wang TF
    Nucleic Acids Res; 2016 Mar; 44(5):2199-213. PubMed ID: 26743002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small ubiquitin-like modifier 1-3 conjugation [corrected] is activated in human astrocytic brain tumors and is required for glioblastoma cell survival.
    Yang W; Wang L; Roehn G; Pearlstein RD; Ali-Osman F; Pan H; Goldbrunner R; Krantz M; Harms C; Paschen W
    Cancer Sci; 2013 Jan; 104(1):70-7. PubMed ID: 23078246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SUMO-modified PCNA recruits Srs2 to prevent recombination during S phase.
    Pfander B; Moldovan GL; Sacher M; Hoege C; Jentsch S
    Nature; 2005 Jul; 436(7049):428-33. PubMed ID: 15931174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of SUMO modification sites in the base excision repair protein, Ntg1.
    Swartzlander DB; McPherson AJ; Powers HR; Limpose KL; Kuiper EG; Degtyareva NP; Corbett AH; Doetsch PW
    DNA Repair (Amst); 2016 Dec; 48():51-62. PubMed ID: 27839712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RAP80 interacts with the SUMO-conjugating enzyme UBC9 and is a novel target for sumoylation.
    Yan J; Yang XP; Kim YS; Joo JH; Jetten AM
    Biochem Biophys Res Commun; 2007 Oct; 362(1):132-138. PubMed ID: 17698038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ubc9 sumoylation controls SUMO chain formation and meiotic synapsis in Saccharomyces cerevisiae.
    Klug H; Xaver M; Chaugule VK; Koidl S; Mittler G; Klein F; Pichler A
    Mol Cell; 2013 Jun; 50(5):625-36. PubMed ID: 23644018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphisms in the UBC9 and PIAS3 genes of the SUMO-conjugating system and breast cancer risk.
    Dünnebier T; Bermejo JL; Haas S; Fischer HP; Pierl CB; Justenhoven C; Brauch H; Baisch C; Gilbert M; Harth V; Spickenheuer A; Rabstein S; Pesch B; Brüning T; Ko YD; Hamann U
    Breast Cancer Res Treat; 2010 May; 121(1):185-94. PubMed ID: 19760037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The RAD6 pathway: control of DNA damage bypass and mutagenesis by ubiquitin and SUMO.
    Ulrich HD
    Chembiochem; 2005 Oct; 6(10):1735-43. PubMed ID: 16142820
    [No Abstract]   [Full Text] [Related]  

  • 20. Targeting Ubc9 for cancer therapy.
    Mo YY; Moschos SJ
    Expert Opin Ther Targets; 2005 Dec; 9(6):1203-16. PubMed ID: 16300471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.